Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Dravet Syndrome: A Rare Epilepsy, Now With Two Approved Treatments

Aug 24 2018

• By Mandy Jackson

FDA approved background, 3D rendering, blue street sign

Related Content

GW's Epidiolex Epilepsy Data Paves Way For Cannabinoids

May 25 2017

Generic Blow Looms For Lundbeck

Aug 08 2018

Gottlieb: Epidiolex Approval Covers One Specific Cannabidiol Medication, Not Marijuana

Jun 25 2018

Takeda/Ovid Broaden Pioneering CH24H Inhibitor To Rare Epilepsies

Jul 20 2018

FDA approves Lundbeck's Onfi for rare, severe epileptic seizures

Oct 26 2011

Latest Japanese recommendations include first nod for Novo's insulin degludec

Sep 04 2012

Related Companies

Biocodex

GW Pharmaceuticals plc

Zogenix, Inc.

H. Lundbeck A/S

PTC Therapeutics, Inc.

New York University School of Medicine

Xenon Pharmaceuticals, Inc.

Biscayne Neurotherapeutics, Inc.

Opko Health

Ovid Therapeutics, Inc.

Takeda Pharmaceutical Co. Ltd.

Additional Topics

Approvals Rare Diseases Pediatrics Research & Development Neurology BioPharmaceutical

More from New Products

More from Scrip

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window